1. Horinek A and Misra M. Does residual renal function decline more rapidly in hemodialysis than in peritoneal dialysis? How good is the evidence? Adv Perit Dial 2004; 20: 137-140. 2004/09/24.
2. Jansen MA, Hart AA, Korevaar JC, et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046-1053. 2002/08/08. DOI: 10.1046/j.1523-1755.2002.00505.x.
3. Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564. 2000/03/07. DOI: 10.1681/asn.V113556.
4. Wang AY and Lai KN. The importance of residual renal function in dialysis patients. Kidney Int 2006; 69: 1726-1732. 2006/04/14. DOI: 10.1038/sj.ki.5000382.
5. Shemin D, Bostom AG, Lambert C, et al. Residual renal function in a large cohort of peritoneal dialysis patients: change over time, impact on mortality and nutrition. Perit Dial Int 2000; 20: 439-444. 2000/09/28.
6. Brener ZZ, Kotanko P, Thijssen S, et al. Clinical benefit of preserving residual renal function in dialysis patients: an update for clinicians. Am J Med Sci 2010; 339: 453-456. 2010/04/09. DOI: 10.1097/MAJ.0b013e3181cf7d5b.
7. Szeto CC, Kwan BC, Chow KM, et al. Predictors of residual renal function decline in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 2015; 35: 180-188. 2014/02/06. DOI: 10.3747/pdi.2013.00075.
8. Johnson DW, Mudge DW, Sturtevant JM, et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int 2003; 23: 276-283. 2003/08/27.
9. Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol 2009; 24: 1445-1452. 2008/12/17. DOI: 10.1007/s00467-008-1046-0.
10. Davalos D and Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012; 34: 43-62. 2011/11/01. DOI: 10.1007/s00281-011-0290-8.
11. Yu J, Lin T, Huang N, et al. Plasma fibrinogen and mortality in patients undergoing peritoneal dialysis: a prospective cohort study. BMC Nephrol 2020; 21: 349. 2020/08/19. DOI: 10.1186/s12882-020-01984-6.
12. Irish A. Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998; 137: 133-139. 1998/05/06. DOI: 10.1016/s0021-9150(97)00273-6.
13. Bargman JM, Thorpe KE and Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162. 2001/09/20. DOI: 10.1681/asn.V12102158.
14. Skeppholm M, Wallén NH, Mobarrez F, et al. Inflammation and thrombin generation cause increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia. Blood Coagul Fibrinolysis 2009; 20: 611-613. 2010/06/04. DOI: 10.1097/MBC.0b013e32833161c5.
15. Levi M and van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38: S26-34. 2010/01/30. DOI: 10.1097/CCM.0b013e3181c98d21.
16. Kaptoge S, White IR, Thompson SG, et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007; 166: 867-879. 2007/09/06. DOI: 10.1093/aje/kwm191.
17. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-299. 2005/04/20. DOI: 10.1016/s0065-3233(05)70008-5.
18. Castell JV, Gómez-Lechón MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-1186. 1990/11/01. DOI: 10.1002/hep.1840120517.
19. Castell JV, Gómez-Lechón MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237-239. 1989/01/02. DOI: 10.1016/0014-5793(89)80476-4.
20. van Oijen M, Witteman JC, Hofman A, et al. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 2005; 36: 2637-2641. 2005/11/05. DOI: 10.1161/01.Str.0000189721.31432.26.
21. Kołodziejczyk J and Ponczek MB. The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression. Contemp Oncol (Pozn) 2013; 17: 113-119. 2013/06/22. DOI: 10.5114/wo.2013.34611.
22. Goldwasser P, Feldman JG, Emiru M, et al. Effect of dialysis modality on plasma fibrinogen concentration: a meta-analysis. Am J Kidney Dis 2004; 44: 941-949. 2004/11/24. DOI: 10.1053/j.ajkd.2004.08.019.
23. Solovjov DA, Pluskota E and Plow EF. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem 2005; 280: 1336-1345. 2004/10/16. DOI: 10.1074/jbc.M406968200.
24. Fan ST and Edgington TS. Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes. J Immunol 1993; 150: 2972-2980. 1993/04/01.
25. Perez RL and Roman J. Fibrin enhances the expression of IL-1 beta by human peripheral blood mononuclear cells. Implications in pulmonary inflammation. J Immunol 1995; 154: 1879-1887. 1995/02/15.
26. Perez RL, Ritzenthaler JD and Roman J. Transcriptional regulation of the interleukin-1beta promoter via fibrinogen engagement of the CD18 integrin receptor. Am J Respir Cell Mol Biol 1999; 20: 1059-1066. 1999/05/05. DOI: 10.1165/ajrcmb.20.5.3281.
27. Skogen WF, Senior RM, Griffin GL, et al. Fibrinogen-derived peptide B beta 1-42 is a multidomained neutrophil chemoattractant. Blood 1988; 71: 1475-1479. 1988/05/01.
28. Sörensen I, Susnik N, Inhester T, et al. Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int 2011; 80: 1035-1044. 2011/07/08. DOI: 10.1038/ki.2011.214.
29. Craciun FL, Ajay AK, Hoffmann D, et al. Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis. Am J Physiol Renal Physiol 2014; 307: F471-484. 2014/07/11. DOI: 10.1152/ajprenal.00189.2014.
30. Drew AF, Tucker HL, Liu H, et al. Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice. Am J Physiol Renal Physiol 2001; 281: F1157-1163. 2001/11/13. DOI: 10.1152/ajprenal.2001.281.6.F1157.
31. Muslimovic A, Rasic S, Tulumovic D, et al. Inflammatory Markers and Procoagulants in Chronic Renal Disease Stages 1-4. Med Arch 2015; 69: 307-310. 2015/12/02. DOI: 10.5455/medarh.2015.69.307-310.
32. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87-92. 2003/01/08. DOI: 10.1161/01.cir.0000042700.48769.59.
33. Hiramoto JS, Katz R, Peralta CA, et al. Inflammation and coagulation markers and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2012; 60: 225-232. 2012/05/09. DOI: 10.1053/j.ajkd.2012.02.335.
34. Gupta J, Mitra N, Kanetsky PA, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 2012; 7: 1938-1946. 2012/10/02. DOI: 10.2215/cjn.03500412.
35. Goicoechea M, de Vinuesa SG, Gómez-Campderá F, et al. Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4. Kidney Int Suppl 2008: S67-70. 2008/11/27. DOI: 10.1038/ki.2008.519.
36. Zoccali C, Mallamaci F, Tripepi G, et al. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003; 254: 132-139. 2003/07/16. DOI: 10.1046/j.1365-2796.2003.01180.x.
37. Amdur RL, Feldman HI, Gupta J, et al. Inflammation and Progression of CKD: The CRIC Study. Clin J Am Soc Nephrol 2016; 11: 1546-1556. 2016/06/25. DOI: 10.2215/cjn.13121215.